Press Releases Elto Pharma to Present and Parti
Post# of 30067
(Total Views: 647)
Posted On: 03/05/2018 8:10:33 AM
Press Releases
Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum
Download as PDF
MARCH 05, 2018
SAN FRANCISCO, March 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., an orphan specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), that is advancing Eltoprazine into a Phase 2b clinical trial for the treatment of the orphan indication Parkinson's disease levodopa-induced dyskinesia (PD-LID), today announced that it will be presenting a summary of its pending Phase 2b PD-LID clinical program and participating in the neuroscience panel at the Sachs BioCapital USA Forum on March 21, 2018 at the New York Academy of Sciences (NYAS) in New York City. The neuroscience panel is entitled "Renewed Approaches for Neuroscience."
"Sachs BioCapital USA Forum is an ideal venue for Elto Pharma to engage with the investment and partnering community," said Gerald Commissiong, interim-CEO of Elto Pharma.
Presentation Details
Company: Elto Pharma (an Amarantus company)
Event: Sachs BioCapital USA Forum
Date: Wednesday, March 21, 2018
Time: 2:20 p.m. EDT for 20 minutes
Presentation Track: Track C
Webcast: Please check www.amarantus.com for details prior to the event
Location: New York Academy of Sciences, New York, NY
About Elto Pharma, Inc.
Elto Pharma, Inc. is developing Eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Alzheimer's aggression and adult attention deficit hyperactivity disorder (adult ADHD). Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile, with statistically significant efficacy results across multiple central nervous system indications. Eltoprazine has received orphan drug designation (ODD) from the US FDA for the treatment of PD-LID.
Eltoprazine was originally developed by Solvay (now Abbvie) in aggression-related indications. The eltoprazine program was out-licensed to PsychoGenics, Inc. (PGI). PGI licensed eltoprazine to Amarantus in 2014 after a successful proof-of-concept trial in PD-LID.
In April 2017, Amarantus incorporated the wholly-owned subsidiary Elto Pharma, Inc. to for the purpose of raising capital to finance the further clinical development of Eltoprazine.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"
. MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS also owns approximately 79.25 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.
For further information please visit www.Amarantus.com, or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Amarantus Investor and Media Contact:
Ascendant Partners, LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings, Inc.
Released March 5, 2018
Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum
Download as PDF
MARCH 05, 2018
SAN FRANCISCO, March 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., an orphan specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), that is advancing Eltoprazine into a Phase 2b clinical trial for the treatment of the orphan indication Parkinson's disease levodopa-induced dyskinesia (PD-LID), today announced that it will be presenting a summary of its pending Phase 2b PD-LID clinical program and participating in the neuroscience panel at the Sachs BioCapital USA Forum on March 21, 2018 at the New York Academy of Sciences (NYAS) in New York City. The neuroscience panel is entitled "Renewed Approaches for Neuroscience."
"Sachs BioCapital USA Forum is an ideal venue for Elto Pharma to engage with the investment and partnering community," said Gerald Commissiong, interim-CEO of Elto Pharma.
Presentation Details
Company: Elto Pharma (an Amarantus company)
Event: Sachs BioCapital USA Forum
Date: Wednesday, March 21, 2018
Time: 2:20 p.m. EDT for 20 minutes
Presentation Track: Track C
Webcast: Please check www.amarantus.com for details prior to the event
Location: New York Academy of Sciences, New York, NY
About Elto Pharma, Inc.
Elto Pharma, Inc. is developing Eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Alzheimer's aggression and adult attention deficit hyperactivity disorder (adult ADHD). Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile, with statistically significant efficacy results across multiple central nervous system indications. Eltoprazine has received orphan drug designation (ODD) from the US FDA for the treatment of PD-LID.
Eltoprazine was originally developed by Solvay (now Abbvie) in aggression-related indications. The eltoprazine program was out-licensed to PsychoGenics, Inc. (PGI). PGI licensed eltoprazine to Amarantus in 2014 after a successful proof-of-concept trial in PD-LID.
In April 2017, Amarantus incorporated the wholly-owned subsidiary Elto Pharma, Inc. to for the purpose of raising capital to finance the further clinical development of Eltoprazine.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"
. MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS also owns approximately 79.25 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016. For further information please visit www.Amarantus.com, or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Amarantus Investor and Media Contact:
Ascendant Partners, LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings, Inc.
Released March 5, 2018
(3)
(0)